Fig. 5: Ablating KCs prevents the hepatic response to atherogenic dyslipidemia.
From: Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult

a, Volcano plot of genes downregulated in female D374Y mice treated with clodronate liposome during 10-d post-tamoxifen administration while maintained on a chow diet (n = 3 versus n = 3; P value from DESeq2 two-sided Wald test). b,c, Effects of clodronate liposomes on the expression of core identity genes of KCs (b), LAMs, monocytes and CV and capsular macrophages (c) in the liver of D374Y mice. d, Effect of clodronate liposomes on the day 10 conserved gene expression in both APOE cKO and D374Y mice. e, IL18BP plasma levels in dyslipidemic APOE cKO and D374Y mice given clodronate liposomes or Dil liposomes controls (ng ml−1, APOE cKO n = 3 and D374Y n = 4). f, Volcano plot and heat map indicating minimal response of the liver to dyslipidemia when comparing littermate control versus D374Y with both treated with clodronate liposomes, as determined by mRNA-seq (n = 3 versus n = 3; P value from DESeq2 two-sided Wald test). g, Total plasma (mg dl−1) and liver (µg mg−1 of protein) cholesterol and triglyceride measurements in dyslipidemic APOE cKO and D374Y mice given clodronate liposomes or Dil liposomes controls with respective littermate controls also administered clodronate liposomes (APOE cKO n = 4 versus n = 3 versus n = 4 and D374Y n = 3 versus n = 4 versus n = 3). h, Plasma CD5l (µg ml−1) concentrations as determined by ELISA in D374Y and littermate control mice 10 d after tamoxifen administration (n = 9 versus n = 9). i, Plasma CD5l (µg ml−1) concentrations in dyslipidemic D374Y mice and littermate control mice given clodronate liposomes and dyslipidemic D374Y mice administered Dil liposomes controls (n = 3 versus n = 4 versus n = 3). All experiments were conducted on day 10 after tamoxifen treatment, and mice were maintained on a normal chow diet. All plots are ±s.e.m. Two-sided t-test (e,h) or one-way ANOVA (g,i).